Starsource Multitrade Ltd
STARSOURCEBSE
₹114.00▼ -1.00 (-0.87%)
Whole company worth₹9 Cr
ProfitLoss-making
1-year range₹70 – ₹153
The short version
Starsource Multitrade, in seven plain questions.
What Starsource Multitrade does
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business.
Worked out from Starsource Multitrade's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Starsource Multitrade is a micro-sized company in pharmaceuticals.
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business.
- Whole company is worth
- ₹9.1 crore
- Run by
- Ruchit Mehta
- Shareholders
- 6,218 people
- Listed since
- 1960
A very small company by stock-market value — prices can swing hard and trading can be thin.
03Does it make money?
For every ₹100 it sells, it spends ₹2336.
Here is where the money from Starsource Multitrade's sales went in FY26, the latest full year it has reported.
₹2264
₹100 of sales ends here
- ₹72Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹2264Running the businessstaff, rent, marketing, power and everything else
- ₹2236Lossspent beyond what came in — covered by savings or new money
On the money its owners have put in
It lost ₹39 for every ₹100 its owners have invested.
Bank FD ~₹6–7
₹-39
₹-50₹-40₹-30₹-20₹-10₹0₹10₹20₹30₹40
Return on equity (ROE) measures the yearly profit made on the money shareholders have put into the business. Negative means the business is eating into that money.
04Is the price high or low?
Starsource Multitrade made a loss, so there is no "price for profit" to measure.
Investors are paying for what they hope it will earn later, not what it earns today. That makes the price harder to judge and more sensitive to news.
The share price over the past year
It is 25% below its highest price of the past year and 63% above its lowest.
05Who owns it?
Its founders and parent group own 28 of every 100 shares — a large stake, though not a majority.
If the company were split into 100 equal shares, this is who would hold them. 6,218 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
One thing going well, two things worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Lost ₹12 crore in its last financial year.
- Thinly traded — only about ₹1 lakh of shares change hands a day, so buying or selling can move the price.
07What happened lately?
Its latest quarter.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹0.1 Cr
Profit
₹0.0 Cr
▲ 100.2% on a year earlier
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Starsource Multitrade?
This page describes Starsource Multitrade using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Starsource Multitrade Ltd (STARSOURCE): company summary
The company's annual net profit swung from a profit of ₹0 crore to a loss of ₹12 crore, while revenue remained at ₹1 crore.
Starsource Multitrade Ltd (STARSOURCE) is a micro-cap Healthcare company valued at ₹9 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Starsource Multitrade Ltd last traded at ₹114, modestly down 0.87% on the day.
- Recent developments
- In June 2026, the company reported a net loss of ₹12 crore for its latest financial year, which is a significant swing from the previous year's ₹0 crore profit. The company is in advanced negotiations to acquire a sick company, which could impact its financial position and business strategy.
- Financial performance
- The company's annual net profit swung from a profit of ₹0 crore to a loss of ₹12 crore, while revenue remained at ₹1 crore. The latest quarter showed a swing from a net loss of ₹12 crore to a profit of ₹0 crore, but revenue and net profit for the quarter were both ₹0 crore.
- Valuation multiples
- A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 8.55 times book value.
- Things to watch
- The company reported a net loss of ₹12 crore in its latest financial year, which is a swing from a profit of ₹0 crore. The latest quarter showed a net loss of ₹12 crore, which swung to a profit of ₹0 crore, but revenue and net profit for the quarter were both ₹0 crore.
- Where it stands
- The company's latest financial year ended with a net loss of ₹12 crore, marking a swing from a profit of ₹0 crore. The latest quarter ended with a net loss of ₹12 crore, which swung to a profit of ₹0 crore, but revenue and net profit for the quarter were both ₹0 crore.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals
Explore Starsource Multitrade Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Starsource Multitrade Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LZYDUS LIFESCIENCES LTDAPOLLO HOSPITALS ENTER. LLAURUS LABS LIMITEDCIPLA LTDDR. REDDY S LABORATORIESMANKIND PHARMA LIMITEDAUROBINDO PHARMA LTDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Starsource Multitrade Ltd with peers
Starsource Multitrade Ltd vs SUN PHARMACEUTICAL IND LStarsource Multitrade Ltd vs DIVI S LABORATORIES LTDStarsource Multitrade Ltd vs TORRENT PHARMACEUTICALS LStarsource Multitrade Ltd vs ZYDUS LIFESCIENCES LTDStarsource Multitrade Ltd vs APOLLO HOSPITALS ENTER. LStarsource Multitrade Ltd vs LAURUS LABS LIMITED
Related tools & concepts
Value Starsource Multitrade Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing